RT - Journal TY - JOUR A1 - Godse, Kiran A1 - Patil, Anant A1 - Godse, Gauri T1 - Ligelizumab: A promising option on the horizon for the management of chronic spontaneous urticaria YR - 2021/1/1 JF - Indian Journal of Drugs in Dermatology JO - Indian J Drugs Dermatol SP - 12 OP - 14 VO - 7 IS - 1 UL - https://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=12;epage=14;aulast=Godse;t=5 DO - 10.4103/ijdd.ijdd_33_20 N2 - Chronic spontaneous urticaria may pose challenges for the treatment in some patients. Different options for the management of chronic urticaria include second-generation antihistamines, leukotriene receptor antagonists, omalizumab (anti-IgE antibody), and immunosuppressants. Omalizumab, a monoclonal antibody, is a valuable option for patients not responding to up-dosing (up to 4 times) of second-generation antihistamine. However, in about one-fourth of the patients, omalizumab may not be effective in controlling symptoms. Considering this, there is a need to identify the drugs for effective treatment. Ligelizumab is a novel anti-IgE monoclonal antibody with higher affinity to IgE than omalizumab. In phase 2b clinical trial, it is found to be effective and well tolerated in patients with chronic spontaneous urticaria. When approved, it may be beneficial for patients who cannot receive or have suboptimal efficacy with omalizumab. ER -